Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 871

1.

Social integration, marital status, and ovarian cancer risk: A 20-year prospective cohort study.

Trudel-Fitzgerald C, Poole EM, Sood AK, Okereke OI, Kawachi I, Kubzansky LD, Tworoger SS.

Psychosom Med. 2019 Oct 4. doi: 10.1097/PSY.0000000000000747. [Epub ahead of print]

PMID:
31592935
2.

Design and Demonstration of High-Efficiency Quantum Well Solar Cells Employing Thin Strained Superlattices.

Welser RE, Polly SJ, Kacharia M, Fedorenko A, Sood AK, Hubbard SM.

Sci Rep. 2019 Sep 27;9(1):13955. doi: 10.1038/s41598-019-50321-x.

3.

Copper-64 Labeled PEGylated Exosomes for In Vivo Positron Emission Tomography and Enhanced Tumor Retention.

Shi S, Li T, Wen X, Wu SY, Xiong C, Zhao J, Lincha VR, Chow DS, Liu Y, Sood AK, Li C.

Bioconjug Chem. 2019 Oct 16;30(10):2675-2683. doi: 10.1021/acs.bioconjchem.9b00587. Epub 2019 Sep 27.

PMID:
31560538
4.

Experimental signatures of a nonequilibrium phase transition near the crossover point of a Langmuir monolayer.

Bera PK, Kandar AK, Krishnaswamy R, Sood AK.

J Phys Condens Matter. 2019 Sep 6;31(50):504004. doi: 10.1088/1361-648X/ab4235. [Epub ahead of print]

PMID:
31491774
5.

Successful Treatment of PAPA Syndrome with Dual Adalimumab and Tacrolimus Therapy.

Sood AK, McShane DB, Googe PB, Wu EY.

J Clin Immunol. 2019 Aug 30. doi: 10.1007/s10875-019-00685-6. [Epub ahead of print] No abstract available.

PMID:
31471736
6.

Placenta-derived extracellular vesicles induce preeclampsia in mouse models.

Han C, Wang C, Chen Y, Wang J, Xu X, Hilton T, Cai W, Zhao Z, Wu Y, Li K, Houck K, Liu L, Sood AK, Wu X, Xue F, Li M, Dong JF, Zhang J.

Haematologica. 2019 Aug 22. pii: haematol.2019.226209. doi: 10.3324/haematol.2019.226209. [Epub ahead of print]

7.

6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.

Yang H, Shu Z, Jiang Y, Mao W, Pang L, Redwood A, Jeter-Jones SL, Jennings NB, Ornelas A, Zhou J, Rodriguez-Aguayo C, Bartholomeusz G, Iles LR, Zacharias NM, Millward SW, Lopez-Berestein G, Le XF, Ahmed AA, Piwnica-Worms H, Sood AK, Bast RC, Lu Z.

Clin Cancer Res. 2019 Sep 15;25(18):5702-5716. doi: 10.1158/1078-0432.CCR-18-3448. Epub 2019 Aug 7.

PMID:
31391192
8.

Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer.

Shuford S, Wilhelm C, Rayner M, Elrod A, Millard M, Mattingly C, Lotstein A, Smith AM, Guo QJ, O'Donnell L, Elder J, Puls L, Weroha SJ, Hou X, Zanfagnin V, Nick A, Stany MP, Maxwell GL, Conrads T, Sood AK, Orr D, Holmes LM, Gevaert M, Crosswell HE, DesRochers TM.

Sci Rep. 2019 Aug 1;9(1):11153. doi: 10.1038/s41598-019-47578-7.

9.

Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?

Chelariu-Raicu A, Coleman RL, Sood AK.

Oncology (Williston Park). 2019 Jul 16;33(7). pii: 629378.

10.

Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.

Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JMG, Dizon T, Coleman RL, Cole SW, Sood AK.

Gynecol Oncol. 2019 Sep;154(3):524-530. doi: 10.1016/j.ygyno.2019.07.004. Epub 2019 Jul 25.

PMID:
31353053
11.

Chromosomal Instability in Tumor Initiation and Development.

Bach DH, Zhang W, Sood AK.

Cancer Res. 2019 Aug 15;79(16):3995-4002. doi: 10.1158/0008-5472.CAN-18-3235. Epub 2019 Jul 26. Review.

PMID:
31350294
12.

Identifying and targeting angiogenesis-related microRNAs in ovarian cancer.

Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Bayraktar R, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, Lacko AG, Sood AK.

Oncogene. 2019 Aug;38(33):6095-6108. doi: 10.1038/s41388-019-0862-y. Epub 2019 Jul 9.

PMID:
31289363
13.

Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options.

Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN.

Oncotarget. 2019 May 28;10(37):3533-3546. doi: 10.18632/oncotarget.26947. eCollection 2019 May 28.

14.

Author Correction: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.

Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan Y.

Nature. 2019 Jun;570(7761):E51. doi: 10.1038/s41586-019-1266-4.

PMID:
31127195
15.

Advancing Drug Development in Gynecologic Malignancies.

Beaver JA, Coleman RL, Arend RC, Armstrong DK, Bala S, Mills GB, Sood AK, Herzog TJ.

Clin Cancer Res. 2019 Aug 15;25(16):4874-4880. doi: 10.1158/1078-0432.CCR-19-0619. Epub 2019 May 24.

PMID:
31126961
16.

Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2019 May 15;25(10):3194. doi: 10.1158/1078-0432.CCR-19-1132. No abstract available.

PMID:
31092618
17.

Corrigendum: FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair.

Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS.

Carcinogenesis. 2019 Jul 20;40(7):936. doi: 10.1093/carcin/bgz062. No abstract available.

18.

Pan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells.

McGuire MH, Herbrich SM, Dasari SK, Wu SY, Wang Y, Rupaimoole R, Lopez-Berestein G, Baggerly KA, Sood AK.

EBioMedicine. 2019 May;43:127-137. doi: 10.1016/j.ebiom.2019.04.045. Epub 2019 May 2.

19.

Strength of Mechanical Memories is Maximal at the Yield Point of a Soft Glass.

Mukherji S, Kandula N, Sood AK, Ganapathy R.

Phys Rev Lett. 2019 Apr 19;122(15):158001. doi: 10.1103/PhysRevLett.122.158001.

PMID:
31050530
20.

Editorial: Cardio-Oncology: From Bench to Bedside.

Abe JI, Sood AK, Martin JF.

Front Cardiovasc Med. 2019 Apr 10;6:37. doi: 10.3389/fcvm.2019.00037. eCollection 2019. No abstract available.

21.

Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.

Gunaratne PH, Pan Y, Rao AK, Lin C, Hernandez-Herrera A, Liang K, Rait AS, Venkatanarayan A, Benham AL, Rubab F, Kim SS, Rajapakshe K, Chan CK, Mangala LS, Lopez-Berestein G, Sood AK, Rowat AC, Coarfa C, Pirollo KF, Flores ER, Chang EH.

Cancer. 2019 Jul 15;125(14):2409-2422. doi: 10.1002/cncr.32053. Epub 2019 Apr 23.

22.

Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients.

Cuneo MG, Szeto A, Schrepf A, Kinner EM, Schachner BI, Ahmed R, Thaker PH, Goodheart M, Bender D, Cole SW, McCabe PM, Sood AK, Lutgendorf SK, Mendez AJ.

Psychoneuroendocrinology. 2019 Aug;106:244-251. doi: 10.1016/j.psyneuen.2019.04.007. Epub 2019 Apr 6.

PMID:
31005045
23.

Trapping and sorting active particles: Motility-induced condensation and smectic defects.

Kumar N, Gupta RK, Soni H, Ramaswamy S, Sood AK.

Phys Rev E. 2019 Mar;99(3-1):032605. doi: 10.1103/PhysRevE.99.032605.

PMID:
30999541
24.

exRNA Atlas Analysis Reveals Distinct Extracellular RNA Cargo Types and Their Carriers Present across Human Biofluids.

Murillo OD, Thistlethwaite W, Rozowsky J, Subramanian SL, Lucero R, Shah N, Jackson AR, Srinivasan S, Chung A, Laurent CD, Kitchen RR, Galeev T, Warrell J, Diao JA, Welsh JA, Hanspers K, Riutta A, Burgstaller-Muehlbacher S, Shah RV, Yeri A, Jenkins LM, Ahsen ME, Cordon-Cardo C, Dogra N, Gifford SM, Smith JT, Stolovitzky G, Tewari AK, Wunsch BH, Yadav KK, Danielson KM, Filant J, Moeller C, Nejad P, Paul A, Simonson B, Wong DK, Zhang X, Balaj L, Gandhi R, Sood AK, Alexander RP, Wang L, Wu C, Wong DTW, Galas DJ, Van Keuren-Jensen K, Patel T, Jones JC, Das S, Cheung KH, Pico AR, Su AI, Raffai RL, Laurent LC, Roth ME, Gerstein MB, Milosavljevic A.

Cell. 2019 Apr 4;177(2):463-477.e15. doi: 10.1016/j.cell.2019.02.018.

25.

Small RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation.

Srinivasan S, Yeri A, Cheah PS, Chung A, Danielson K, De Hoff P, Filant J, Laurent CD, Laurent LD, Magee R, Moeller C, Murthy VL, Nejad P, Paul A, Rigoutsos I, Rodosthenous R, Shah RV, Simonson B, To C, Wong D, Yan IK, Zhang X, Balaj L, Breakefield XO, Daaboul G, Gandhi R, Lapidus J, Londin E, Patel T, Raffai RL, Sood AK, Alexander RP, Das S, Laurent LC.

Cell. 2019 Apr 4;177(2):446-462.e16. doi: 10.1016/j.cell.2019.03.024.

PMID:
30951671
26.

The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research.

Das S; Extracellular RNA Communication Consortium, Ansel KM, Bitzer M, Breakefield XO, Charest A, Galas DJ, Gerstein MB, Gupta M, Milosavljevic A, McManus MT, Patel T, Raffai RL, Rozowsky J, Roth ME, Saugstad JA, Van Keuren-Jensen K, Weaver AM, Laurent LC.

Cell. 2019 Apr 4;177(2):231-242. doi: 10.1016/j.cell.2019.03.023. Review.

PMID:
30951667
27.

GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.

Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK.

Mol Cancer Ther. 2019 May;18(5):969-979. doi: 10.1158/1535-7163.MCT-18-0770. Epub 2019 Mar 29.

PMID:
30926640
28.

Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis.

Azam SH, Porrello A, Harrison EB, Leslie PL, Liu X, Waugh TA, Belanger A, Mangala LS, Lopez-Berestein G, Wilson HL, McCann JV, Kim WY, Sood AK, Liu J, Dudley AC, Pecot CV.

Oncogene. 2019 Jun;38(26):5191-5210. doi: 10.1038/s41388-019-0786-6. Epub 2019 Mar 27.

PMID:
30918328
29.

Circular RNAs in Cancer.

Bach DH, Lee SK, Sood AK.

Mol Ther Nucleic Acids. 2019 Jun 7;16:118-129. doi: 10.1016/j.omtn.2019.02.005. Epub 2019 Feb 16. Review.

30.

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.

Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L.

Cancer. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5.

PMID:
30835824
31.

Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.

Matsuo K, Machida H, Mandelbaum RS, Grubbs BH, Roman LD, Sood AK, Gershenson DM.

Gynecol Oncol. 2019 May;153(2):230-237. doi: 10.1016/j.ygyno.2019.02.003. Epub 2019 Feb 20.

PMID:
30797590
32.

Performance of the MasSpec Pen for Rapid Diagnosis of Ovarian Cancer.

Sans M, Zhang J, Lin JQ, Feider CL, Giese N, Breen MT, Sebastian K, Liu J, Sood AK, Eberlin LS.

Clin Chem. 2019 May;65(5):674-683. doi: 10.1373/clinchem.2018.299289. Epub 2019 Feb 15.

PMID:
30770374
33.

Gamma tocopherol effect on LPS-induced sputum neutrophilia is not modified by BMI or GSTM1 genotype.

Sood AK, Burbank AJ, Duran CG, Enders K, Zhou H, Peden DB, Hernandez ML.

J Allergy Clin Immunol. 2019 May;143(5):1937-1939. doi: 10.1016/j.jaci.2018.12.1009. Epub 2019 Jan 17. No abstract available.

PMID:
30660638
34.

PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.

Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G.

EBioMedicine. 2019 Feb;40:290-304. doi: 10.1016/j.ebiom.2018.11.045. Epub 2019 Jan 14.

35.

Leucocytosis before liver transplant, source could be hiding in heart: Case report.

Tandon M, Kumaraswamy P, Sood AK, Pamecha V.

Indian J Anaesth. 2018 Dec;62(12):1000-1002. doi: 10.4103/ija.IJA_473_18. No abstract available.

36.

Exploring and comparing adverse events between PARP inhibitors.

LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL.

Lancet Oncol. 2019 Jan;20(1):e15-e28. doi: 10.1016/S1470-2045(18)30786-1. Review.

PMID:
30614472
37.

Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts.

Radhakrishnan R, Ha JH, Jayaraman M, Liu J, Moxley KM, Isidoro C, Sood AK, Song YS, Dhanasekaran DN.

Cancer Lett. 2019 Feb 1;442:464-474. doi: 10.1016/j.canlet.2018.11.023. Epub 2018 Nov 29.

PMID:
30503552
38.

Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.

Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G.

EBioMedicine. 2018 Dec;38:100-112. doi: 10.1016/j.ebiom.2018.11.004. Epub 2018 Nov 25.

39.

EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis.

An J, Du Y, Fan X, Wang Y, Ivan C, Zhang XG, Sood AK, An Z, Zhang N.

Oncogene. 2019 Mar;38(12):2123-2134. doi: 10.1038/s41388-018-0565-9. Epub 2018 Nov 19.

40.

Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.

Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Ming-Yang S, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK.

Mol Cancer Ther. 2019 Feb;18(2):421-436. doi: 10.1158/1535-7163.MCT-18-0365. Epub 2018 Nov 12.

PMID:
30420565
41.

Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases.

Salcedo MP, Sood AK, Dos Reis R, Ramalingam P, Chen C, Frumovitz M, Jhingran A, Pitcher B, Ramirez PT, Schmeler KM.

Gynecol Oncol. 2019 Jan;152(1):101-105. doi: 10.1016/j.ygyno.2018.10.035. Epub 2018 Nov 3.

PMID:
30396690
42.

Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer.

Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND.

Gynecol Oncol. 2018 Dec;151(3):428-432. doi: 10.1016/j.ygyno.2018.10.017. Epub 2018 Oct 23.

PMID:
30366647
43.

PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.

Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AK.

Mol Cancer Ther. 2019 Jan;18(1):162-172. doi: 10.1158/1535-7163.MCT-17-1050. Epub 2018 Oct 10.

PMID:
30305341
44.

Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers.

Yuan J, Hu Z, Mahal BA, Zhao SD, Kensler KH, Pi J, Hu X, Zhang Y, Wang Y, Jiang J, Li C, Zhong X, Montone KT, Guan G, Tanyi JL, Fan Y, Xu X, Morgan MA, Long M, Zhang Y, Zhang R, Sood AK, Rebbeck TR, Dang CV, Zhang L.

Cancer Cell. 2018 Oct 8;34(4):549-560.e9. doi: 10.1016/j.ccell.2018.08.019.

45.

Bone protection by inhibition of microRNA-182.

Inoue K, Deng Z, Chen Y, Giannopoulou E, Xu R, Gong S, Greenblatt MB, Mangala LS, Lopez-Berestein G, Kirsch DG, Sood AK, Zhao L, Zhao B.

Nat Commun. 2018 Oct 5;9(1):4108. doi: 10.1038/s41467-018-06446-0.

46.

A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.

Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN.

Gynecol Oncol. 2018 Nov;151(2):374-380. doi: 10.1016/j.ygyno.2018.08.037. Epub 2018 Sep 10. Review.

PMID:
30213435
47.

Shedding Light on the Dark Cancer Genomes: Long Noncoding RNAs as Novel Biomarkers and Potential Therapeutic Targets for Cancer.

Zhang L, Peng D, Sood AK, Dang CV, Zhong X.

Mol Cancer Ther. 2018 Sep;17(9):1816-1823. doi: 10.1158/1535-7163.MCT-18-0124. Review.

48.

CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.

Byeon Y, Lee JW, Choi WS, Won JE, Kim GH, Kim MG, Wi TI, Lee JM, Kang TH, Jung ID, Cho YJ, Ahn HJ, Shin BC, Lee YJ, Sood AK, Han HD, Park YM.

Cancer Res. 2018 Nov 1;78(21):6247-6256. doi: 10.1158/0008-5472.CAN-17-3871. Epub 2018 Aug 16.

PMID:
30115698
49.

Bioactive lipid metabolism in platelet "first responder" and cancer biology.

Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, Overman M, Honn K, Menter DG.

Cancer Metastasis Rev. 2018 Sep;37(2-3):439-454. doi: 10.1007/s10555-018-9755-8. Review.

PMID:
30112590
50.

Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.

Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK.

Obstet Gynecol. 2018 Sep;132(3):545-554. doi: 10.1097/AOG.0000000000002796.

Supplemental Content

Loading ...
Support Center